PineTree Therapeutics
Cambridge, Massachusetts, United States · Biotechnology, Health Care · 35 employees
Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor™ platform enables selective degradation of membrane-bound and extracellular proteins, offering a differentiated mech
Funding history
- Series SERIES B — $47.0M — Oct 2025
- Series series a — $23.5M — Jun 2022
Recent signals
- Oct 29, 2025: Raised $47.0M in Series SERIES B
- Jun 07, 2022: Raised $23.5M in Series series a
See plans & pricing → Track PineTree Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.